Combined with our previous findings that BA has anti-inflammatory activity through inhibiting the activation of NF-κB and NLRP3 inflammasome signaling pathway in PMNP treated with HPS, we provide evidence that BA could be a novel therapeutic intervention for the treatment of Glasser’s disease. This evidence concerns the gene NFKB1 and Hermansky-Pudlak syndrome.